What is the recommended approach for anticoagulation therapy in a patient with atrial fibrillation (AF), using the CHADS2VASc (Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes, Stroke or transient ischemic attack) score and the HASBLED (Hypertension, Abnormal renal or liver function, Stroke, Bleeding, Labile INR, Elderly, Drugs or alcohol) score to assess stroke and bleeding risks?

Anticoagulation Strategy Using CHA₂DS₂-VASc and HAS-BLED Scores in Atrial Fibrillation

Use CHA₂DS₂-VASc to identify who needs anticoagulation (score ≥1 in males or ≥2 in females warrants oral anticoagulation), then use HAS-BLED to identify modifiable bleeding risk factors and flag patients needing closer monitoring—but a high HAS-BLED score (≥3) is NOT a reason to withhold anticoagulation. 1

Step 1: Stroke Risk Assessment with CHA₂DS₂-VASc

Calculate the CHA₂DS₂-VASc score for all AF patients, including those with paroxysmal AF: 1, 2

• Congestive heart failure or LVEF ≤40%: 1 point
• Hypertension: 1 point
• Age ≥75 years: 2 points
• Diabetes mellitus: 1 point
• Prior stroke, TIA, or thromboembolism: 2 points
• Vascular disease (prior MI, peripheral artery disease, aortic plaque): 1 point
• Age 65-74 years: 1 point
• Female sex: 1 point 2, 3

Treatment decisions based on score: 1, 2

• Score = 0 in males or 1 in females (lone AF, age <65): No antithrombotic therapy recommended 1
• Score ≥1 in males or ≥2 in females: Oral anticoagulation definitively recommended 1, 2, 3

The CHA₂DS₂-VASc score has superior sensitivity compared to older CHADS₂ scoring and reliably identifies truly low-risk patients who can safely avoid anticoagulation. 1 This applies equally to paroxysmal, persistent, and permanent AF—the stroke risk is identical regardless of AF pattern. 3

Step 2: Bleeding Risk Assessment with HAS-BLED

Calculate HAS-BLED score for all AF patients at every patient contact: 1, 2

• Hypertension (uncontrolled, >160 mmHg systolic): 1 point
• Abnormal renal function (dialysis, transplant, creatinine >2.6 mg/dL): 1 point
• Abnormal liver function (cirrhosis or bilirubin >2x normal or AST/ALT >3x normal): 1 point
• Stroke history: 1 point
• Bleeding history or predisposition (anemia, prior major bleed): 1 point
• Labile INR (if on warfarin, time in therapeutic range <60%): 1 point
• Elderly (age >65 years): 1 point
• Drugs (antiplatelet agents, NSAIDs) or alcohol excess (≥8 drinks/week): 1 point each 4, 2

Interpretation and action: 1

• HAS-BLED ≥3: Identifies patients at higher bleeding risk who warrant more frequent review and follow-up, with aggressive attention to modifiable risk factors 1, 2
• Critical point: A high HAS-BLED score is rarely a reason to avoid anticoagulation—it serves to identify modifiable bleeding risk factors that should be addressed 1, 4

The HAS-BLED score outperforms stroke risk scores (CHADS₂ and CHA₂DS₂-VASc) for predicting serious bleeding and should be used specifically for bleeding risk assessment. 5 However, stroke and bleeding risks are correlated but not exchangeable—most patients have equal or lower bleeding risk compared to their stroke risk category. 6

Step 3: Anticoagulant Selection

Direct oral anticoagulants (DOACs) are recommended as first-line therapy over warfarin: 2, 3

• Preferred DOACs: Apixaban, rivaroxaban, dabigatran, or edoxaban 2, 3
• Rationale: DOACs have predictable pharmacodynamics, similar or lower major bleeding rates, and significant reduction in hemorrhagic stroke compared to warfarin 2, 7

Warfarin is preferred over DOACs only for: 2, 8

• Moderate or severe mitral stenosis
• Mechanical prosthetic heart valves 2, 8

For warfarin therapy (if used): 8

• Target INR 2.0-3.0 (target 2.5) for most AF patients 4, 8
• Time in therapeutic range should be ≥65% for optimal efficacy 1

Step 4: Address Modifiable Bleeding Risk Factors

At every patient contact, actively manage modifiable bleeding risk factors: 1

• Control hypertension (target <160/90 mmHg)
• Discontinue concomitant NSAIDs or aspirin in anticoagulated patients (unless specific indication like recent ACS/PCI)
• Reduce alcohol consumption to <8 drinks/week
• Optimize renal and liver function where possible
• Treat underlying bleeding predispositions (e.g., gastric ulcer, anemia) 1
• For warfarin patients with labile INR, consider switching to DOAC or implementing self-monitoring 1

Common Pitfalls to Avoid

Do not use HAS-BLED as a contraindication to anticoagulation. The score identifies patients who need closer monitoring and modification of risk factors, not patients who should be denied stroke prevention therapy. 1, 4, 2 The benefit of stroke prevention outweighs bleeding risk in almost all patients with CHA₂DS₂-VASc ≥1 (males) or ≥2 (females). 1, 2

Do not use stroke risk scores (CHADS₂ or CHA₂DS₂-VASc) to predict bleeding risk. While these scores correlate with bleeding, HAS-BLED demonstrates significantly better discriminatory performance for bleeding events and should be used specifically for bleeding risk assessment. 5, 9

Do not withhold anticoagulation due to fear of falls. A patient would need to fall approximately 300 times per year for the risk of intracranial hemorrhage to outweigh the stroke prevention benefit. 4

Schedule patients with HAS-BLED ≥3 for more frequent follow-up (every 3-6 months rather than annually) to reassess bleeding risk factors and ensure adherence, as bleeding risk is highly dynamic. 1